Events & Webinars

Key TakeawaysThe EU HTA Regulation will take effect on January 12, 2025. Joint Clinical Assessments (JCAs) will begin with innovative cancer and cell...

Key TakeawaysThe EU Health Summit will address critical challenges in European healthcare. Topics include ageing populations, chronic diseases, and workforce pressures. The event...

Key TakeawaysStefan Dr. Walzer announces the AI for Pharma Market Access course in collaboration with CELforPharma. The 2-day course empowers pharma professionals to...

Key TakeawaysThe EU HTA Regulation will apply from 12 January 2025, introducing Joint Clinical Assessments (JCA) for innovative therapies. By 2028, JCAs will...

Key TakeawaysStar Therapeutics will present its innovative pipeline, including VGA039, at the J.P. Morgan Healthcare Conference. The conference presentation will provide insights into...

Key TakeawaysIran’s emergency system integrates AI and telemedicine to enhance patient care. AI applications in emergency medicine discussed at the 17th Annual Emergency...

Key TakeawaysBristol Myers Squibb (BMS) will present at J.P. Morgan’s 43rd Annual Healthcare Conference on January 13, 2025. A fireside chat and live...

Key TakeawaysTessera Therapeutics presents preclinical breakthroughs in genome engineering for sickle cell disease and T-cell therapies. Gene Writing achieved high efficiency in rewriting...

Key TakeawaysUtilizes proprietary technologies like VelociSuite for optimized antibody production. Employs data-driven insights from the Regeneron Genetics Center to identify new therapeutic targets. ...

Key TakeawayswAIHA patients frequently undergo invasive surgeries and require repeat blood transfusions due to ineffective current treatments. Sentiment analysis reveals significant patient dissatisfaction...

Key TakeawaysNuvisertib’s combination with other therapies could enhance treatment efficacy for MF patients Enzomenib’s targeted approach may lead to personalized treatment plans for...

Key TakeawaysZiftomenib’s high remission rates suggest it could become a frontline treatment option for AML patients with specific genetic profiles. The manageable safety...

Key TakeawaysYescarta’s consistent survival rates suggest it remains a reliable option for second-line therapy in R/R LBCL. Improvements in managing CRS and ICANS...

Key TakeawaysLivaNova's CORE-VNS study provides robust real-world evidence supporting VNS Therapy's efficacy. VNS Therapy demonstrates sustained benefits in both adult and pediatric populations...

Key TakeawaysBayer's focus on AI integration indicates a strategic move towards automating and enhancing diagnostic processes in radiology. The introduction of lower-dose contrast...